Zoetis Enters High-Volume Veterinary Chemistry Testing Market
CarystaTM HVC system offers greater efficiency, productivity
to veterinary clinics and laboratories
PARSIPPANY, N.J.—Feb. 5, 2018—Zoetis announced today the launch of CarystaTM HVC (High Volume Chemistry), a stand-alone, chemistry diagnostic instrument designed to bring reference-lab quality testing to high-volume veterinary practices.
Carysta HVC offers a menu of 37 routine and specialty parameters, available as singly selected tests or fully customizable panels, all on one system. The instrument offers veterinarians greater operational flexibility than current instrument solutions, while improving quality, productivity, and reducing clinic costs of testing. Availability is expected in March 2018. Carysta HVC is specifically designed for those veterinary practices conducting the highest volume of diagnostic tests, as such practices would benefit from the increased throughput of the instrument.
“Zoetis is bringing to market an innovative, high-quality diagnostic instrument specifically designed for veterinary use,” said Richard E. Goldstein, DVM, DACVIM, DECVIM-CA, Executive Director and Chief Medical Officer of U.S. Diagnostics.
Carysta HVC is based on liquid reagent technology ideally suited for veterinary clinics, reference laboratories, and shelters that need greater throughput and test selection flexibility.
The easy-to-use system runs multiple patient samples simultaneously with minimal sample volumes, enabling high-volume veterinary clinics to practice cost-effective medicine based on patient needs and allowing customized test selection based on veterinary requirements. It also gives veterinarians the ability to add urgent samples with no work flow interruption.
Carysta HVC will be distributed through an exclusive partnership with DiaSys Diagnostic Systems, USA, LLC.
“The HVC instrument will assist high-volume veterinary clinics and regional laboratories to gain improved productivity at a lower cost, while obtaining reference laboratory-quality results. The instrument’s innovative design enables our veterinary customers to achieve greater throughput and high-level test performance,” said Lisa Lee, Vice President, U.S. Diagnostics and Business Solutions at Zoetis.
Carysta HVC is part of a growing commitment to veterinary diagnostics, enabling Zoetis to support veterinarians in their ability to predict, detect, prevent and treat disease. Customers can learn more about Carysta HVC at www.carysta.com and by visiting the Diagnostics booth at VMX in Orlando, Fla., through Feb. 7, and Western Veterinary Conference in Las Vegas, March 4-8.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetisus.com.
For further information contact:
Coyne Public Relations
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States